ライフサイエンスコーパス: dexamethasone

1 therapy (triamcinolone, bevacizumab, and/or dexamethasone).

2 ase inhibitor ouabain), and corticosteroids (dexamethasone).

3 olerated dose of melflufen 40 mg plus weekly dexamethasone.

4 enetoclax versus placebo plus bortezomib and dexamethasone.

5 ntly induced by the synthetic corticosteroid dexamethasone.

6 pha, IL-6, and IL-8 at a similar efficacy to dexamethasone.

7 ed in combination with alkylating agents and dexamethasone.

8 global changes in gene expression induced by dexamethasone.

9 of isatuximab with pomalidomide and low-dose dexamethasone.

10 id beta42 oligomers, lipopolysaccharides, or dexamethasone.

11 neurons following explant when treated with dexamethasone.

12 d dexamethasone compared with bortezomib and dexamethasone.

13 and were increased by the aromatase inducer dexamethasone.

14 tly higher levels of virus when treated with dexamethasone.

15 ntiation in the presence of interleukin 4 or dexamethasone.

16 esistant to the anti-inflammatory effects of dexamethasone.

17 omide-dexamethasone, and 153 to pomalidomide-dexamethasone.

18 viral regulatory proteins was stimulated by dexamethasone.

19 e was 40 mg of melflufen in combination with dexamethasone.

20 eekly, plus subcutaneous bortezomib and oral dexamethasone.

21 0 (95% CI, 1.09-4.87) for ciprofloxacin plus dexamethasone.

22 s, including TGF-beta signaling, affected by dexamethasone.

23 e that reflected CFS, rescue medication use (dexamethasone 0.1% 4 times daily), and corneal ulceratio

24 ts received zoledronic acid (7.5 ug/kg) plus dexamethasone (1 mg/kg).

25 15; lenalidomide 15 mg orally on days 1-21; dexamethasone 12 mg orally on days 1, 18, and 15 every 2

26 entration of EDCs detected in the muscle was dexamethasone (2.37-15.84 ng/g) and (0.77-13.41 ng/g), i

27 t 24 weeks and once per week thereafter) and dexamethasone (20 mg four times per week for the first 2

28 on days 1, 4, 8, and 11 every 21 days), and dexamethasone (20 mg orally on days 1, 2, 4, 5, 8, 9, 11

29 mg/m(2) subcutaneously or intravenously and dexamethasone (20 mg orally).

30 bortezomib (1.3 mg/m(2) once per week), and dexamethasone (20 mg twice per week), or bortezomib (1.3

31 We administered oral selinexor (80 mg) plus dexamethasone (20 mg) twice weekly to patients with myel

32 tuximab 10 mg/kg plus pomalidomide 4 mg plus dexamethasone 40 mg (20 mg for patients aged >=75 years)

33 de 4 mg daily on days 1-21 and oral low-dose dexamethasone 40 mg on days 1, 8, 15, and 22 in 28-day c

34 ral lenalidomide 25 mg on days 1-21 and oral dexamethasone 40 mg on days 1, 8, 15, and 22 of repeated

35 r 30 min on day 1 in 21-day cycles plus oral dexamethasone 40 mg weekly and did not receive melflufen

36 aged >=75 years), or pomalidomide 4 mg plus dexamethasone 40 mg.

37 ose, escalated to 70 mg/m(2) thereafter) and dexamethasone (40 mg/wk).

38 ess frequent with selinexor, bortezomib, and dexamethasone (41 [21%] patients) than with bortezomib a

39 (41 [21%] patients) than with bortezomib and dexamethasone (70 [34%] patients; odds ratio 0.50 [95% C

40 trial, however, revealed that treatment with dexamethasone, a classic synthetic glucocorticoid, enhan

41 Treatment with dexamethasone, a GR activator, also induces changes in t

42 Dexamethasone abolished systemic cytokine synthesis and

43 Immediate pretreatment dexamethasone administration was inversely associated wi

44 sone (daratumumab group) or lenalidomide and dexamethasone alone (control group).

45 domide and dexamethasone or lenalidomide and dexamethasone alone using an interactive voice or integr

46 an among those who received lenalidomide and dexamethasone alone.

47 ciently as a synthetic glucocorticoid (e.g., Dexamethasone) an induced skin atopic dermatitis, an ind

48 s were given a combination of melflufen plus dexamethasone and 13 patients were given single-agent me

49 st one dose of pomalidomide, bortezomib, and dexamethasone and 270 patients received at least one dos

50 al of 2104 patients were assigned to receive dexamethasone and 4321 to receive usual care.

51 t evaluable) with selinexor, bortezomib, and dexamethasone and 9.46 months (8.11-10.78) with bortezom

52 lease like progesterone, ZnSO(4), quercetin, dexamethasone and apomorphine were active in models of A

53 poorer tolerance to chemotherapy, especially dexamethasone and asparaginase, and have increased risk

54 To address the dexamethasone and CPI question, we conducted a systemati

55 Interestingly, the synthetic corticosteroid dexamethasone and GR or KLF15 alone had little effect on

56 es using lenalidomide and/or bortezomib with dexamethasone and HDIVig led to a significant improvemen

57 asone or cyclophosphamide, lenalidomide, and dexamethasone) and achieved a partial or minimal respons

58 to treatment: 154 to isatuximab-pomalidomide-dexamethasone, and 153 to pomalidomide-dexamethasone.

59 a were randomly assigned 2:1 to carfilzomib, dexamethasone, and daratumumab (KdD) or carfilzomib and

60 pare the efficacy and safety of carfilzomib, dexamethasone, and daratumumab versus carfilzomib and de

61 acin plus hydrocortisone, ciprofloxacin plus dexamethasone, and neomycin plus hydrocortisone.

62 ginase intensification, the use of induction dexamethasone, and the safe omission of cranial radiothe

63 received at least one dose of bortezomib and dexamethasone, and these patients were included in safet

64 izumab recommended that all patients receive dexamethasone as a component of the prophylactic antieme

65 upports use of pomalidomide, bortezomib, and dexamethasone as a treatment option in patients with rel

66 n multiple myeloma, both in combination with dexamethasone as well as in triplet regimens with additi

67 proval of the XPO1 inhibitor selinexor (plus dexamethasone) as a fifth-line therapy for patients with

68 ) genotype influenced the clinical impact of dexamethasone, as observed in tuberculous meningitis.

69 gned patients to receive oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 1

70 randomly assigned to receive bortezomib plus dexamethasone (BD), or BD plus cyclophosphamide (C-BD).

71 the efficacy and safety of bendamustine with dexamethasone (ben-dex) in patients with persistent or p

72 Here, we demonstrate that dexamethasone blocks interleukin-1 production in both bo

73 eactions were permitted for pomalidomide and dexamethasone, but not for isatuximab.

74 peripheral blood mononuclear cells, MPA and dexamethasone, but not NET-A, upregulated (median [inter

75 which HLH-directed therapy (as etoposide and dexamethasone) can be life-saving.

76 tients received bortezomib, doxorubicin, and dexamethasone chemotherapy, and were then followed up fo

77 sting greater activity in the melflufen plus dexamethasone cohort.

78 ced antileukemic activity by quizartinib and dexamethasone combination has been validated using prima

79 n treated with pomalidomide, bortezomib, and dexamethasone compared with bortezomib and dexamethasone

80 benefit of isatuximab plus pomalidomide and dexamethasone compared with pomalidomide and dexamethaso

81 The synthetic corticosteroid dexamethasone consistently induces BoHV-1 reactivation f

82 ted with cyclophosphamide, lenalidomide, and dexamethasone (CRD) or CTD.

83 ated with cyclophosphamide, thalidomide, and dexamethasone (CTD) (22.5% [n = 121 of 538] vs 16.1% [n

84 lophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD) induction had higher risk of VTE co

85 tment with cyclophosphamide, bortezomib, and dexamethasone (CVD) versus no intensification treatment

86 yloidosis, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is considered standard of care.

87 aratumumab plus bortezomib, thalidomide, and dexamethasone (D-VTd) significantly improved rates of st

88 one intravenously daily for 5 days, 10 mg of dexamethasone daily for 5 days or until ICU discharge, p

89 to receive daratumumab plus lenalidomide and dexamethasone (daratumumab group) or lenalidomide and de

90 ith advanced AL receiving either daratumumab/dexamethasone (DD, n = 106) or daratumumab/bortezomib/de

91 We investigated interactions between the GC dexamethasone (DEX) and the bone resorptive agents 1,25(

92 erapy for HLH consists of the glucocorticoid dexamethasone (DEX) and the chemotherapeutic agent etopo

93 eceptor (GR) by the synthetic corticosteroid dexamethasone (DEX) stimulates bovine herpesvirus 1 (BoH

94 ted and divided randomly into control (C) or dexamethasone (Dex) treatment at day 14 out of the 21-da

95 For testing, pregnant mice were administered dexamethasone (DEX), a synthetic GC, in the last trimest

96 ma cell line BWTG3, as evidenced by impaired Dexamethasone (Dex)-stimulated direct GR-dependent gene

97 lutinin (PHA), in the presence or absence of dexamethasone (Dex).

98 henol curcumin (CURC) and the corticosteroid dexamethasone (DEX).

99 feasibility of this strategy, five different dexamethasone (Dex, a potent GC)-containing monomers wit

100 study, in human NK cells, the glucocorticoid dexamethasone downregulated LIMK expression, F-actin acc

101 These dexamethasone-driven IL-10(+) cells, and predominantly t

102 ipants received aprepitant, ondansetron, and dexamethasone during and 2 days after chemotherapy.

103 Among the 45 patients given melflufen plus dexamethasone during phase 2, the most common grade 3-4

104 sone (DD, n = 106) or daratumumab/bortezomib/dexamethasone (DVD, n = 62).

105 Om ASCs were resistant to these dexamethasone effects; recombinant TGFBR3 increased thei

106 We previously reported dexamethasone enhanced the pro-fibrotic effects of trans

107 17beta-estradiol equivalents/L)-, GR (60 ng dexamethasone equivalents/L)-, and PPARgamma-mediated ac

108 Dexamethasone exhibited diverse regulation of gene expre

109 reated by treating rats with zoledronate and dexamethasone, extracting teeth, and immediately injecti

110 d, double-blind, placebo-controlled trial of dexamethasone for patients with a symptomatic chronic su

111 nation with subcutaneous bortezomib and oral dexamethasone for this indication.

112 Here, we compared the penetration of dexamethasone from an ethanolic hydroxyethyl cellulose g

113 no clinical evidence to warrant omission of dexamethasone from guideline-compliant prophylactic anti

114 d in the pembrolizumab plus lenalidomide and dexamethasone group (cardiac arrest, cardiac failure, my

115 hasone group (n=125) or the pomalidomide and dexamethasone group (n=124).

116 ther the pembrolizumab plus pomalidomide and dexamethasone group (n=125) or the pomalidomide and dexa

117 hasone group (n=151) or the lenalidomide and dexamethasone group (n=150).

118 d to the pembrolizumab plus lenalidomide and dexamethasone group (n=151) or the lenalidomide and dexa

119 d in the pembrolizumab plus pomalidomide and dexamethasone group (one each of unknown cause, neutrope

120 up (sepsis) and two (1%) in the pomalidomide-dexamethasone group (pneumonia and urinary tract infecti

121 patient (<1%) in the isatuximab-pomalidomide-dexamethasone group (sepsis) and two (1%) in the pomalid

122 bolism) and two (1%) in the lenalidomide and dexamethasone group (upper gastrointestinal haemorrhage

123 Overall, 482 patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usu

124 patients (8%) in the isatuximab-pomalidomide-dexamethasone group and 14 (9%) in the pomalidomide-dexa

125 6.2-19.8] for the selinexor, bortezomib, and dexamethasone group and 16.5 months [9.4-19.8] for the b

126 -195 (49%) to the selinexor, bortezomib, and dexamethasone group and 207 (51%) to the bortezomib and

127 ter randomization - 375 were assigned to the dexamethasone group and 373 to the placebo group.

128 ) patients in the selinexor, bortezomib, and dexamethasone group and 62 (30%) in the bortezomib and d

129 performed in 6 of 349 patients (1.7%) in the dexamethasone group and in 25 of 350 patients (7.1%) in

130 ported in 286 of 341 patients (83.9%) in the dexamethasone group and in 306 of 339 patients (90.3%) i

131 curred in 278 of 1417 infants (19.6%) in the dexamethasone group and in 331 of 1406 infants (23.5%) i

132 ) in the pembrolizumab plus lenalidomide and dexamethasone group and pneumonia (eight [6%]) and sepsi

133 one group and 62 (30%) in the bortezomib and dexamethasone group died.

134 Patients randomized to the dexamethasone group had a mean 6.6 ventilator-free days

135 At 7 days, patients in the dexamethasone group had a mean SOFA score of 6.1 (95% CI

136 1 to the pembrolizumab plus pomalidomide and dexamethasone group or the pomalidomide and dexamethason

137 The isatuximab-pomalidomide-dexamethasone group received isatuximab intravenously on

138 More adverse events occurred in the dexamethasone group than in the placebo group.

139 s in the pembrolizumab plus pomalidomide and dexamethasone group versus 56 (46%) of 121 patients in t

140 s in the pembrolizumab plus lenalidomide and dexamethasone group versus 57 (39%) patients in the lena

141 CI 8.9-13.9) in the isatuximab-pomalidomide-dexamethasone group versus 6.5 months (4.5-8.3) in the p

142 ) in the pembrolizumab plus pomalidomide and dexamethasone group versus 8.4 months (5.9-not reached)

143 dexamethasone group or the pomalidomide and dexamethasone group via an interactive voice response or

144 5 patients in the selinexor, bortezomib, and dexamethasone group vs 35 [17%] of 204 in the bortezomib

145 Thirty-three patients (21.9%) in the dexamethasone group vs 43 (29.1%) in the standard care g

146 oup vs 35 [17%] of 204 in the bortezomib and dexamethasone group), fatigue (26 [13%] vs two [1%]), an

147 In the dexamethasone group, the incidence of death was lower th

148 ne group and 207 (51%) to the bortezomib and dexamethasone group-and the first dose of study medicati

149 hasone group and 14 (9%) in the pomalidomide-dexamethasone group.

150 nd sepsis (two [1%]) in the lenalidomide and dexamethasone group.

151 deaths were reported in the pomalidomide and dexamethasone group.

152 46%) of 121 patients in the pomalidomide and dexamethasone group.

153 6.5 months [9.4-19.8] for the bortezomib and dexamethasone group.

154 ewer repeat operations were performed in the dexamethasone group.

155 sus 6.5 months (4.5-8.3) in the pomalidomide-dexamethasone group; hazard ratio 0.596, 95% CI 0.44-0.8

156 hs (5.9-not reached) in the pomalidomide and dexamethasone group; progression-free survival estimates

157 us 57 (39%) patients in the lenalidomide and dexamethasone group; the most common serious adverse eve

158 Dexamethasone had no effects on IL-13-induced hyperrespo

159 Lenalidomide and dexamethasone has been a standard of care in transplant-

160 Selinexor combined with dexamethasone has shown activity in patients with heavil

161 Venetoclax plus bortezomib and dexamethasone has shown encouraging clinical efficacy wi

162 9.46 months (8.11-10.78) with bortezomib and dexamethasone (hazard ratio 0.70 [95% CI 0.53-0.93], p=0

163 nterior chamber migration of an intravitreal dexamethasone implant (Ozurdex(R)).

164 The intravitreal dexamethasone implant (Ozurdex) is effective for the tre

165 ctive review of 640 consecutive intravitreal dexamethasone implant injections was conducted from Febr

166 nterior chamber migration of an intravitreal dexamethasone implant is a serious complication.

167 Dexamethasone implant is an effective and safe treatment

168 ries present a high risk of anterior chamber dexamethasone implant migration.

169 se patients who experienced anterior chamber dexamethasone implant migrations were identified, as wel

170 d to evaluate the effect of the intravitreal dexamethasone implant Ozurdex(R) in patients with differ

171 d DME, primary therapy with the intravitreal dexamethasone implant PRN (for 2 years) resulted in sign

172 Intravitreal dexamethasone implant was noninferior to ITA at 8 weeks

173 injection (e.g. Ozurdex(R), an intravitreal dexamethasone implant).

174 different response patterns to intravitreal dexamethasone implants (IDI) in naive and previously tre

175 ear positive relationship with the number of dexamethasone implants before FAc implant (P = .002, R(2

176 mg/m(2) intravenously) with 40 mg of weekly dexamethasone in 28-day cycles until disease progression

177 fety profile of isatuximab plus pomalidomide/dexamethasone in heavily pretreated patients with RRMM.

178 dexamethasone versus standard bortezomib and dexamethasone in patients with previously treated multip

179 We did a phase 1-2 study of melflufen and dexamethasone in patients with relapsed and refractory m

180 dexamethasone compared with pomalidomide and dexamethasone in patients with relapsed and refractory m

181 sone, and daratumumab versus carfilzomib and dexamethasone in patients with relapsed or refractory mu

182 s to evaluate venetoclax plus bortezomib and dexamethasone in patients with relapsed or refractory mu

183 study evaluated isatuximab plus pomalidomide/dexamethasone in patients with relapsed/refractory multi

184 ial evaluated the efficacy of melflufen plus dexamethasone in relapsed and refractory multiple myelom

185 reparation and data analysis, the amounts of dexamethasone in RHS, detected and quantified by STXM an

186 he only inputs are concentration profiles of dexamethasone in skin at three consecutive penetration t

187 maximum tolerated dose in the melflufen plus dexamethasone in the combination cohort..

188 nterferon-gamma antibody), administered with dexamethasone, in an open-label, single-group, phase 2-3

189 -2 doses, both alone and in combination with dexamethasone, increased the proportion of single IL-10(

190 with bortezomib (a proteasome inhibitor) and dexamethasone induced high response rates with low rates

191 n putative half-GREs that were important for dexamethasone induced promoter activity.

192 omoted myotube differentiation and prevented dexamethasone-induced atrophy in myotubes in vitro.

193 BMAds, in turn, provided resistance to dexamethasone-induced cell-cycle arrest and apoptosis, i

194 gptl4 has also been shown to be required for dexamethasone-induced hepatic ceramide production.

195 in base subunit 1 (SPTLC1)/SPTLC2, decreased dexamethasone-induced plasma and liver triglyceride leve

196 LF15, are induced in TG neurons early during dexamethasone-induced reactivation.

197 A-mediated knockdowns of GR and DPP4 blocked dexamethasone-induced THP1-MPhi migration.

198 ere significantly associated with changes in dexamethasone-induced transrepression of NF-kappaB.

199 yclopentanedione (ACPD), had lower levels of dexamethasone-induced triglyceride accumulation in plasm

200 R activation by the synthetic corticosteroid dexamethasone influenced virus shedding during reactivat

201 Dexamethasone initiated after the first week of life red

202 the penetration of the antiinflammatory drug dexamethasone into the skin layers by the one-dimensiona

203 a for retinitis pigmentosa, Dextenza (0.4 mg dexamethasone intracanalicular insert) for ocular inflam

204 Twenty mg of dexamethasone intravenously daily for 5 days, 10 mg of d

205 Authority of India to examine the safety of dexamethasone intravitreal (DEX) implant over 1 year in

206 ated with different alternatives, among them Dexamethasone intravitreal implant 0.7 mg (DEX 0.7) has

207 r-week regimen of selinexor, bortezomib, and dexamethasone is a novel, effective, and convenient trea

208 sensitivity of erythroid differentiation to dexamethasone is dependent on the developmental origin o

209 Additionally, dexamethasone is shown to inhibit downstream effectors o

210 ofile of pembrolizumab plus pomalidomide and dexamethasone is unfavourable for patients with relapsed

211 ne, and daratumumab (KdD) or carfilzomib and dexamethasone (Kd).

212 In ENDEAVOR, carfilzomib (56 mg/m(2)) and dexamethasone (Kd56) demonstrated longer progression-fre

213 ation (ASCT) into a carfilzomib-lenalidomide-dexamethasone (KRd) regimen for patients with newly diag

214 Carfilzomib-lenalidomide-dexamethasone (KRd) therapy has yielded promising result

215 ibitor, in combination with lenalidomide and dexamethasone (KRd), has shown promising efficacy in pha

216 .78 ng/g), and in the reproductive organ are dexamethasone (<2.54-37.23 ng/g) and caffeine (0.21-18.9

217 g/g) and (0.77-13.41 ng/g), in the liver was dexamethasone (<2.54-43.56 ng/g) and progesterone (2.23-

218 mAv was conjugated with Dexamethasone (mAv-Dex), a broad-spectrum glucocorticoid

219 Oral melphalan and dexamethasone (MDex) were considered a standard of care

220 n-free survival compared with bortezomib and dexamethasone (median 11.20 months [95% CI 9.66-13.73] v

221 Akt1 and Ak2, but not Akt3, impaired GR- and dexamethasone-mediated transactivation of the BoHV-1 imm

222 We assessed the impact of dexamethasone on cytokine concentration dynamics and the

223 lenalidomide on days 1-14, and 20 mg of oral dexamethasone on days 1, 2, 4, 5, 8, 9, 11, and 12.

224 to 21 in each cycle, and oral or intravenous dexamethasone on days 1, 8, 15, and 22 of each cycle.

225 lenalidomide on days 1-21, and 40 mg of oral dexamethasone on days 1, 8, 15, and 22.

226 Kip1, significantly attenuated the impact of dexamethasone on erythroid differentiation and inhibited

227 a, to evaluate the effect of MPA, NET-A, and dexamethasone on Mtb containment in monocyte-derived mac

228 The effect of dexamethasone on outcomes in patients with chronic subdu

229 kedly refractory to the inhibitory effect of dexamethasone on proliferation and IL-2Ralpha expression

230 lophosphamide, vincristine, doxorubicin, and dexamethasone) on courses 1, 3, 5, and 7 alternating wit

231 protocol (cyclophosphamide, thalidomide, and dexamethasone or cyclophosphamide, lenalidomide, and dex

232 participants were assigned to intramuscular dexamethasone or identical placebo.

233 e either pembrolizumab plus lenalidomide and dexamethasone or lenalidomide and dexamethasone alone us

234 ipants were randomised to a 2-week course of dexamethasone or placebo in addition to receiving standa

235 ect the effects of illegal administration of dexamethasone or prednisolone or 17beta-estradiol on Cha

236 logical blockade of ER stress in vitro using dexamethasone or the chemical chaperones TUDCA and 4PBA

237 MPA (P < .005) and dexamethasone (P < .01), but not NET-A, significantly at

238 After symptomatic measures and high-dose dexamethasone, patients were randomly assigned to receiv

239 moderate or severe ARDS, use of intravenous dexamethasone plus standard care compared with standard

240 rted in patients who received bortezomib and dexamethasone (pneumonia [n=1], hepatic encephalopathy [

241 s who received pomalidomide, bortezomib, and dexamethasone (pneumonia [n=2], unknown cause [n=2], car

242 CR-like" signaling with multiple TKIs and/or dexamethasone prevented this signaling plasticity and in

243 echanisms of harm and test 2 hypotheses: (1) dexamethasone reduced proinflammatory cytokine concentra

244 Intravitreal dexamethasone reduced the requirement of enucleation or

245 ity of the panobinostat plus bortezomib plus dexamethasone regimen.

246 lytic PP2A subunit (Ppp2ca) had no effect on dexamethasone responses on plasma and liver triglyceride

247 s during the index admission, treatment with dexamethasone resulted in fewer favorable outcomes and m

248 ients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among t

249 Selinexor-dexamethasone resulted in objective treatment responses

250 ay is GC-responsive since treating mice with dexamethasone resulted in reduced muscle expression of m

251 at risk for early preterm birth, the use of dexamethasone resulted in significantly lower risks of n

252 C.I. 1.14-1.39), lower doses of concomitant dexamethasone (RR: 1.36; 95% C.I. 1.02-1.81), not receiv

253 Lenalidomide, bortezomib, and dexamethasone (RVd) followed by autologous stem cell tra

254 combination of lenalidomide, bortezomib, and dexamethasone (RVD) is a highly effective and convenient

255 ur subsequent cycles of len, bortezomib, and dexamethasone (RVD; AHCT + RVD), all followed by len unt

256 Melflufen plus dexamethasone showed clinically meaningful efficacy and

257 Dexamethasone showed lower anti-inflammatory effects in

258 Pomalidomide, bortezomib, and dexamethasone significantly improved progression-free su

259 The addition of isatuximab to pomalidomide-dexamethasone significantly improves progression-free su

260 this study, we show that the glucocorticoid dexamethasone significantly increased IL-10 production b

261 to receive a 2-week tapering course of oral dexamethasone, starting at 8 mg twice daily, or placebo.

262 Furthermore, GR and dexamethasone stimulate productive infection and promote

263 emonstrate that the synthetic corticosteroid dexamethasone stimulated explant-induced reactivation fr

264 profile, became phagocytic, and responded to dexamethasone stimulation, characteristic of TM cells.

265 In Abdsc ASCs, low concentrations of dexamethasone suppressed TGFbeta signaling and enhanced

266 o received daratumumab plus lenalidomide and dexamethasone than among those who received lenalidomide

267 Emerging data indicate that dexamethasone therapy reduces 28-day mortality in patien

268 The antiviral drug remdesivir, dexamethasone, transfusion of convalescent plasma, and u

269 We establish that tumours from dexamethasone-treated mice exhibit reduced infiltration

270 vealed the induction of distinct proteins in dexamethasone-treated PB and CB erythroid progenitors.

271 These findings, therefore, demonstrate that dexamethasone treatment can have direct detrimental off-

272 le isotope-labeling technique, we found that dexamethasone treatment induced the rate of hepatic de n

273 Overall, our results indicate that chronic dexamethasone treatment induces an ANGPTL4-ceramide-PKCz

274 Furthermore, preemptive dexamethasone treatment of DSS-challenged SAMP mice led

275 Dexamethasone treatment of erythroid-differentiated PB,

276 Dexamethasone treatment of PB progenitors resulted in th

277 that interleukin-1 signalling inhibition and dexamethasone treatment share therapeutic efficacies and

278 Perturbation of Schlemm's canal cells with dexamethasone treatment, alpha-actinin overexpression, o

279 flammation and could be partially rescued by dexamethasone treatment.

280 ced neutrophilic inflammation in response to dexamethasone treatment.

281 Dexamethasone upregulated TGFBR1, and TGFBR2 in the pres

282 Dexamethasone use might attenuate lung injury in these p

283 sion-free survival (PFS) over bortezomib and dexamethasone (Vd) in patients with relapsed/refractory

284 benefit of weekly selinexor, bortezomib, and dexamethasone versus standard bortezomib and dexamethaso

285 ll patients received a 3-drug induction with dexamethasone, vincristine, and pegaspargase (PEG) and w

286 Bortezomib, lenalidomide, and dexamethasone (VRd) is a standard therapy for newly diag

287 e events (any grade; isatuximab-pomalidomide-dexamethasone vs pomalidomide-dexamethasone) were infusi

288 survival versus bortezomib, thalidomide, and dexamethasone (VTd) in patients with newly diagnosed mul

289 Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell transplant

290 y between both groups, despite the fact that dexamethasone was omitted in the FMD group.

291 Patients received 40 mg dexamethasone weekly (20 mg for patients >=75 years old

292 Chicken embryos exposed to dexamethasone were growth restricted and showed systolic

293 ammatory responses to lipopolysaccharide and dexamethasone were unchanged.

294 b-pomalidomide-dexamethasone vs pomalidomide-dexamethasone) were infusion reactions (56 [38%] vs 0),

295 utine use; and corticosteroids, specifically dexamethasone, were recommended for temporary symptomati

296 xorubicin, ABT-199 (a Bcl-2 antagonist), and dexamethasone when tested on hematological cancer cells.

297 Moreover, the effect of dexamethasone, which enhanced the inhibition of nerve fi

298 the efficacy and safety of lenalidomide and dexamethasone with and without pembrolizumab in patients

299 ssed efficacy and safety of pomalidomide and dexamethasone with or without pembrolizumab in patients

300 ly assigned patients (1:1) to bortezomib and dexamethasone with or without pomalidomide using a permu